Abstract
BACKGROUND: To verify overall survival predictions made with residual convolutional neural network-determined morphological response (ResNet-MR) in patients with unresectable synchronous liver-only metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy (BBC). METHODS: A retrospective review of liver-only mCRC patients treated with BBC from December 2011 to Apr 2021 was performed. Patients who had metachronous liver metastases or received locoregional treatment before the initiation of BBC were excluded. The percentage of downstaging to curative treatment and overall survival (OS) were recorded. Two abdominal radiologists evaluated portal venous phase CT images based on the morphological criteria and divided the images into Groups 1, 2, and 3. These images were used to establish the radiologists-determined morphological response (RD-MR), which classified patients into responders and non-responders based on the morphological change 3 months after the initiation of BBC. Then, the Group 1 and 3 images classified by the radiologists were input into ResNet as the training dataset. The trained ResNet then redivided the Group 2 images into Groups 1, 2 and 3. The ResNet-MR was determined on the basis of these redivided images and the initial Group 1 and 3 images classified by the radiologists. RESULTS: Eighty-four patients were included in this study (53 males and 31 females, with a median age of 60.0 years). The follow-up time ranged from 10 to 86 months. A total of 407 CT images were input into ResNet as the training dataset. Both RD-MR and ResNet-MR correlated with OS (p value = 0.0167 and 0.0225, respectively). Regarding discriminatory ability for mortality, ResNet-MR had higher area under curve than RD-MR at both 1 year and 2 years and showed a significant difference in discriminatory ability (p-value = 0.0321) at 2 years. RD-MR classified 28 patients (33.3%) as responders, and ResNet-MR classified an additional 16 patients (19.0%) as responders; these 16 patients had longer OS than the remaining non-responders in the RD-MR group (27.49 versus 21.20 months, p value = 0.043) and had a higher percentage of downstaging (37.5% versus 17.5%, p value = 0.1610). CONCLUSIONS: In CRC patients with liver metastases treated with BBC, prediction of survival can be improved with the aid of ResNet, enabling optimized individualized treatment.